Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report

We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzum, Astrid, Trave, Ilaria, D’Agostino, Federica, Burlando, Martina, Cozzani, Emanuele, Parodi, Aurora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Vaccine Society 2022
Materias:
COVID-19 Special
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200649/
https://www.ncbi.nlm.nih.gov/pubmed/35799871
http://dx.doi.org/10.7774/cevr.2022.11.2.222
Descripción
Sumario:We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivation. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been associated with an up-regulated T helper type 1-cell response, possibly favoring an immune system imbalance. Also, EBV reactivation has been postulated after COVID-19 vaccination, but only in the immunosuppressed. Noteworthy we report the first case of EBV viral reactivation associated with cutaneous manifestations in an immunocompetent patient after the COVID-19 vaccine.

Ejemplares similares